A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

Vikas Gupta, Ruben A. Mesa, Michael W.N. Deininger, Candido E. Rivera, Shireen Sirhan, Carrie Baker Brachmann, Helen Collins, Jun Kawashima, Yan Xin, and Srdan Verstovsek

Disclosures: Conflict of interest disclosure: VG served on an advisory board for, received research funding from, and received honorarium from Novartis/Icyte Corporation. RAM received consulting fees from Novartis; received research funding from Incyte Corporation, Gilead Sciences, Inc., CTI BioPharma Corp, Promedior, Inc., NS Pharma Inc., and Genentech, Inc.; received honorarium from Novartis. MWND has received consulting fees from ARIAD Pharmaceuticals, Inc., Incyte Corporation, Novartis, and Pfizer Inc.; received research funding from Bristol Myers Squibb, Celgene, Gilead Sciences, Inc., and Novartis; served on an advisory board/Board of Directors for ARIAD Pharmaceuticals, Inc., CTI BioPharma Corp, Incyte Corporation, Novartis, and Pfizer Inc. CER served on an advisory board/Board of Directors for Cephalon; received research funding from Gilead Sciences, Inc., Nippon Shinyaku Co., LTD, Celgene, Eli Lilly and Company, and Pfizer Inc. SS has received honorarium from Novartis. CBB is employed by Gilead Sciences, Inc. and was previously employed by Celgene; owns stock and/or holds ownership in Gilead Sciences, Inc., Celgene, and Vertex. HC is employed by Gilead Sciences, Inc. JK is employed by, owns stock and/or holds ownership in, and received research funding from Gilead Sciences, Inc. YX is employed by and owns stock and/or holds ownership in Gilead Sciences, Inc. SV received research funding from Gilead Sciences, Inc.

Contributions: Contribution: VG designed research, enrolled patients in the trial, performed research, collected data, analyzed/interpreted data, and wrote the manuscript; RAM designed research, performed research, contributed vital new reagents or analytical tools, collected data, analyzed/interpreted data, and wrote the manuscript; MWND performed research, collected data, analyzed/interpreted data, and wrote the manuscript; CER performed research, collected data, and analyzed/interpreted data; SS collected data and wrote the manuscript; CBB analyzed/interpreted data and wrote the manuscript; HC designed research, analyzed/interpreted data, and wrote the manuscript; JK designed research, performed research, collected data, analyzed/interpreted data, and reviewed the manuscript; YX analyzed/interpreted data and wrote the manuscript; SV designed research, performed research, collected data, analyzed/interpreted data, and wrote the manuscript.